Yasushi Hamaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasushi Hamaya has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Osawa
Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
32 shared publications - Moriya Iwaizumi
Department of Laboratory Medicine Hamamatsu University School of Medicine Shizuoka Japan
28 shared publications - Takahisa Furuta
Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
24 shared publications Ken Sugimoto
First Department of Medicine Hamamatsu University School of Medicine Shizuoka Japan
22 shared publicationsMihoko Yamade
First Department of Medicine Hamamatsu University School of Medicine Shizuoka Japan
14 shared publications- Ken Sugimoto
First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan
13 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Ectopic gastric squamous metaplasia with concomitant well-differentiated adenocarcinoma: a case report
Gastric squamous metaplasia is a rare condition whose clinical significance and malignant potential remain unclear. Most reported cases are located in the
- 18 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessEctopic gastric squamous metaplasia with concomitant well-differentiated adenocarcinoma: a case report
Gastric squamous metaplasia is a rare condition whose clinical significance and malignant potential remain unclear. Most reported cases are located in the
- Open Access
- 10 July 2026
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 32, e953332
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects - Article abstract #953332
- 10 July 2026
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 32, e953332
Open AccessEffect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects - Article abstract #953332
- Open Access
A Prospective Study Comparing the Diagnostic Ability of Abdominal Ultrasonography with Computed Tomography in Cases Suspected of Retaining the Patency Capsule
Objectives: Patency capsule (PC) testing is widely used to assess small‐bowel patency before small‐bowel capsule endoscopy (SBCE). Although abdominal computed tomography (CT) reliably identifies PC location, routine use is limited by radiation exposure and cost. Abdominal ultrasonography (AUS) is a noninvasive, radiation‐free alternative; however, its diagnostic accuracy for PC localization remains unclear. Methods: We conducted a prospective, exploratory, single‐center study in patients in whom PC excretion could not be confirmed within the predefined observation period. All patients underwent AUS followed by CT on the same day. The primary endpoint was the sensitivity of AUS for detecting small‐bowel PC retention using CT as the reference standard. Secondary endpoints included the PC visualization rate, diagnostic accuracy for small bowel versus colon classification, six‐segment agreement between AUS and CT, and SBCE retention after AUS‐based assessment. Results: Thirty‐four patients were included. AUS visualized the PC in 28 patients (82.4%). All six patients with small‐bowel retention on CT were correctly identified as “small bowel” by AUS (sensitivity 100%; 95% confidence interval [CI], 61.0–100). Among 28 patients with colonic PC on CT, AUS classified 22 as “colon,” yielding a sensitivity of 78.6% (95% CI, 60.5–89.9). Six‐segment agreement between AUS and CT was 82.4% overall and 100% among visualized cases. No SBCE retention occurred after AUS‐based colonic classification. Conclusions: AUS accurately detected small‐bowel PC retention and showed good agreement with CT when visualization was achieved. Although non‐visualized findings require cautious interpretation, AUS may serve as a useful first‐line imaging modality for evaluating PC location prior to SBCE. Trial Registration: N/A.
Open AccessA Prospective Study Comparing the Diagnostic Ability of Abdominal Ultrasonography with Computed Tomography in Cases Suspected of Retaining the Patency Capsule
Objectives: Patency capsule (PC) testing is widely used to assess small‐bowel patency before small‐bowel capsule endoscopy (SBCE). Although abdominal computed tomography (CT) reliably identifies PC location, routine use is limited by radiation exposure and cost. Abdominal ultrasonography (AUS) is a noninvasive, radiation‐free alternative; however, its diagnostic accuracy for PC localization remains unclear. Methods: We conducted a prospective, exploratory, single‐center study in patients in whom PC excretion could not be confirmed within the predefined observation period. All patients underwent AUS followed by CT on the same day. The primary endpoint was the sensitivity of AUS for detecting small‐bowel PC retention using CT as the reference standard. Secondary endpoints included the PC visualization rate, diagnostic accuracy for small bowel versus colon classification, six‐segment agreement between AUS and CT, and SBCE retention after AUS‐based assessment. Results: Thirty‐four patients were included. AUS visualized the PC in 28 patients (82.4%). All six patients with small‐bowel retention on CT were correctly identified as “small bowel” by AUS (sensitivity 100%; 95% confidence interval [CI], 61.0–100). Among 28 patients with colonic PC on CT, AUS classified 22 as “colon,” yielding a sensitivity of 78.6% (95% CI, 60.5–89.9). Six‐segment agreement between AUS and CT was 82.4% overall and 100% among visualized cases. No SBCE retention occurred after AUS‐based colonic classification. Conclusions: AUS accurately detected small‐bowel PC retention and showed good agreement with CT when visualization was achieved. Although non‐visualized findings require cautious interpretation, AUS may serve as a useful first‐line imaging modality for evaluating PC location prior to SBCE. Trial Registration: N/A.
- Open Access
Primary Anaplastic Lymphoma Kinase‐Positive Inflammatory Myofibroblastic Tumor of the Small Bowel Detected by Capsule Endoscopy: A Case Report
Primary inflammatory myofibroblastic tumor (IMT) of the small intestine is rare, and its endoscopic characteristics remain poorly defined. We report a case of anaplastic lymphoma kinase (ALK)‐positive small bowel IMT detected by capsule endoscopy (CE). A 24‐year‐old woman presented with epigastric pain. Contrast‐enhanced computed tomography revealed a 2‐cm mass in the small intestine. Double‐balloon endoscopy was attempted but failed to reach the lesion. CE demonstrated a submucosal tumor‐like protrusion with mild surface erythema and conspicuous whitish villous changes. Laparoscopy‐assisted partial resection of the small intestine was performed, and histopathological examination with immunohistochemistry confirmed ALK‐positive IMT. The postoperative course was uneventful, and no recurrence was observed during 8 months of follow‐up. This case indicates that CE can provide clinically useful information for the evaluation of small bowel submucosal lesions beyond the reach of conventional endoscopy. IMT should be considered in the differential diagnosis of erythematous small bowel tumors in young patients.
Open AccessPrimary Anaplastic Lymphoma Kinase‐Positive Inflammatory Myofibroblastic Tumor of the Small Bowel Detected by Capsule Endoscopy: A Case Report
Primary inflammatory myofibroblastic tumor (IMT) of the small intestine is rare, and its endoscopic characteristics remain poorly defined. We report a case of anaplastic lymphoma kinase (ALK)‐positive small bowel IMT detected by capsule endoscopy (CE). A 24‐year‐old woman presented with epigastric pain. Contrast‐enhanced computed tomography revealed a 2‐cm mass in the small intestine. Double‐balloon endoscopy was attempted but failed to reach the lesion. CE demonstrated a submucosal tumor‐like protrusion with mild surface erythema and conspicuous whitish villous changes. Laparoscopy‐assisted partial resection of the small intestine was performed, and histopathological examination with immunohistochemistry confirmed ALK‐positive IMT. The postoperative course was uneventful, and no recurrence was observed during 8 months of follow‐up. This case indicates that CE can provide clinically useful information for the evaluation of small bowel submucosal lesions beyond the reach of conventional endoscopy. IMT should be considered in the differential diagnosis of erythematous small bowel tumors in young patients.
- Open Access
- 29 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2609
Real-World Evaluation of an AI-Assisted Diagnostic Support System for Early Gastric Cancer: Diagnostic Performance, Confidence Stratification, and Determinants of False-Positive Diagnosis
Background/Objectives: Artificial intelligence (AI)-assisted endoscopy has shown high sensitivity for early gastric cancer detection; however, false-positive diagnoses remain a clinical challenge. This study aimed to evaluate the real-world diagnostic performance of a commercially available AI system and to identify factors associated with false-positive diagnoses, focusing on repeated AI evaluations and confidence stratification. Methods: This single-center retrospective study included 47 patients with 89 localized gastric lesions evaluated between March 2024 and March 2025. Endoscopic examinations were performed under white-light, non-magnified observation with repeated AI assessments of each lesion. The rates of “Consider biopsy” (B) judgments were calculated. Lesions with a B judgment rate of ≥50% were defined as AI-positive and classified into four AI confidence categories. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Factors associated with false-positive diagnoses were analyzed using penalized logistic regression. Results: The AI system demonstrated a sensitivity of 97.6% and an NPV of 95.7%, with a specificity of 45.8%. Pathology-positive rates decreased stepwise across the four AI confidence categories (p < 0.001). Among AI-positive lesions, low regional reproducibility, lesion size ≥ 30 mm, scar, and erosion were independently associated with false-positive diagnoses. In analyses restricted to non-neoplastic lesions, lesion size ≥ 30 mm remained significantly associated with false-positive diagnosis. Conclusions: In real-world clinical practice, a commercially available AI system provides high sensitivity for early gastric cancer detection. Incorporating confidence stratification and regional reproducibility into clinical decision-making may enhance the effective use of AI-assisted endoscopic diagnosis beyond binary interpretations.
- 29 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2609
Open AccessReal-World Evaluation of an AI-Assisted Diagnostic Support System for Early Gastric Cancer: Diagnostic Performance, Confidence Stratification, and Determinants of False-Positive Diagnosis
Background/Objectives: Artificial intelligence (AI)-assisted endoscopy has shown high sensitivity for early gastric cancer detection; however, false-positive diagnoses remain a clinical challenge. This study aimed to evaluate the real-world diagnostic performance of a commercially available AI system and to identify factors associated with false-positive diagnoses, focusing on repeated AI evaluations and confidence stratification. Methods: This single-center retrospective study included 47 patients with 89 localized gastric lesions evaluated between March 2024 and March 2025. Endoscopic examinations were performed under white-light, non-magnified observation with repeated AI assessments of each lesion. The rates of “Consider biopsy” (B) judgments were calculated. Lesions with a B judgment rate of ≥50% were defined as AI-positive and classified into four AI confidence categories. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Factors associated with false-positive diagnoses were analyzed using penalized logistic regression. Results: The AI system demonstrated a sensitivity of 97.6% and an NPV of 95.7%, with a specificity of 45.8%. Pathology-positive rates decreased stepwise across the four AI confidence categories (p < 0.001). Among AI-positive lesions, low regional reproducibility, lesion size ≥ 30 mm, scar, and erosion were independently associated with false-positive diagnoses. In analyses restricted to non-neoplastic lesions, lesion size ≥ 30 mm remained significantly associated with false-positive diagnosis. Conclusions: In real-world clinical practice, a commercially available AI system provides high sensitivity for early gastric cancer detection. Incorporating confidence stratification and regional reproducibility into clinical decision-making may enhance the effective use of AI-assisted endoscopic diagnosis beyond binary interpretations.
- Open Access
- 12 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (15) , e35647
Ustekinumab effectiveness in Crohn’s disease with lesions in the intestines
Ustekinumab is prescribed for the treatment of patients with steroid-resistant moderate to severe Crohn’s disease. We investigated its clinical outcome in patients with small and large intestinal lesions. Patients who were newly administered ustekinumab between March 2014 and December 2020 at Hamamatsu University Hospital were included in the study. The primary endpoint was Crohn’s disease activity index score at baseline and weeks 8, 24, and 48 after the initiation of treatment, and secondary endpoints were albumin, hemoglobin, and C-reactive protein at these time points. Ustekinumab treatment retention was examined in both groups; the 2 groups were compared using the Friedman test, Mann–Whitney U test, or Fisher exact test. Overall, Crohn’s disease activity index scores improved between baseline and 48 weeks, but the difference was not significant. However, there was a significant improvement between baseline and 48 weeks in patients with lesions in the small intestine only. Overall, patients showed significant improvement in albumin levels between baseline and 48 weeks but not in C-reactive protein or hemoglobin levels. When limited to patients with lesions in the small intestine, albumin and hemoglobin levels showed significant improvement. Both types showed high rates of treatment retention, although there was no significant difference. Ustekinumab appears to be a safe and effective treatment option that may be particularly effective in patients with lesions in the small intestine only.
- 12 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (15) , e35647
Open AccessUstekinumab effectiveness in Crohn’s disease with lesions in the intestines
Ustekinumab is prescribed for the treatment of patients with steroid-resistant moderate to severe Crohn’s disease. We investigated its clinical outcome in patients with small and large intestinal lesions. Patients who were newly administered ustekinumab between March 2014 and December 2020 at Hamamatsu University Hospital were included in the study. The primary endpoint was Crohn’s disease activity index score at baseline and weeks 8, 24, and 48 after the initiation of treatment, and secondary endpoints were albumin, hemoglobin, and C-reactive protein at these time points. Ustekinumab treatment retention was examined in both groups; the 2 groups were compared using the Friedman test, Mann–Whitney U test, or Fisher exact test. Overall, Crohn’s disease activity index scores improved between baseline and 48 weeks, but the difference was not significant. However, there was a significant improvement between baseline and 48 weeks in patients with lesions in the small intestine only. Overall, patients showed significant improvement in albumin levels between baseline and 48 weeks but not in C-reactive protein or hemoglobin levels. When limited to patients with lesions in the small intestine, albumin and hemoglobin levels showed significant improvement. Both types showed high rates of treatment retention, although there was no significant difference. Ustekinumab appears to be a safe and effective treatment option that may be particularly effective in patients with lesions in the small intestine only.
- Open Access
- 25 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3110
Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.
- 25 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3110
Open AccessExpectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.
- Open Access
- 6 January 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (1) , e0280279
A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study
Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is one of the most serious complications of ERCP. Various procedures can reduce the incidence of PEP, such as wire-guided cannulation, prophylactic pancreatic stent placement, and pretreatment anal insertion of NSAIDs. Recently, iso-osmolar contrast media (IOCM) have been used for ERCP in several hospitals to reduce the risk of PEP in Japan. However, the effect of IOCM is uncertain because few reports have examined IOCM in relation to PEP. Aim: This study aimed to investigate the relationship between contrast media used and the incidence of PEP. Methods: This retrospective study included all qualifying patients who had undergone ERCP at Hamamatsu University Hospital between January 2012 and January 2020. This study examined whether there was a difference in the onset of PEP between patients administered IOCM and high osmolar contrast medium (HOCM). Propensity score matching was used to analyze patient characteristics and ERCP procedures. Amidotrizoic acid was used as HOCM and iodixanol as IOCM. Results: ERCP was performed on 458 patients, and 830 procedures were conducted. After propensity score matching, 162 patients from the amidotrizoic acid group and 162 patients from the iodixanol group were selected. The incidence of PEP was 10.5% (17) in the amidotrizoic acid group and 9.3% (15) in the iodixanol group (P = 0.71). Changes in serum amylase levels post- and pre-ERCP were 240.6 ± 573.8 U/L and 142.7 ± 382.1 U/L in the amidotrizoic acid and iodixanol groups, respectively (P = 0.072). Conclusion: Iodixanol had no prophylactic effect on PEP and clinical outcomes.
- 6 January 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (1) , e0280279
Open AccessA comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study
Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is one of the most serious complications of ERCP. Various procedures can reduce the incidence of PEP, such as wire-guided cannulation, prophylactic pancreatic stent placement, and pretreatment anal insertion of NSAIDs. Recently, iso-osmolar contrast media (IOCM) have been used for ERCP in several hospitals to reduce the risk of PEP in Japan. However, the effect of IOCM is uncertain because few reports have examined IOCM in relation to PEP. Aim: This study aimed to investigate the relationship between contrast media used and the incidence of PEP. Methods: This retrospective study included all qualifying patients who had undergone ERCP at Hamamatsu University Hospital between January 2012 and January 2020. This study examined whether there was a difference in the onset of PEP between patients administered IOCM and high osmolar contrast medium (HOCM). Propensity score matching was used to analyze patient characteristics and ERCP procedures. Amidotrizoic acid was used as HOCM and iodixanol as IOCM. Results: ERCP was performed on 458 patients, and 830 procedures were conducted. After propensity score matching, 162 patients from the amidotrizoic acid group and 162 patients from the iodixanol group were selected. The incidence of PEP was 10.5% (17) in the amidotrizoic acid group and 9.3% (15) in the iodixanol group (P = 0.71). Changes in serum amylase levels post- and pre-ERCP were 240.6 ± 573.8 U/L and 142.7 ± 382.1 U/L in the amidotrizoic acid and iodixanol groups, respectively (P = 0.072). Conclusion: Iodixanol had no prophylactic effect on PEP and clinical outcomes.
- Open Access
- 7 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (40) , e31017
Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study
Eosinophilic infiltration is sometimes observed histologically in ulcerative colitis (UC), but the effect of the degree of infiltration on the treatment course for UC is not completely understood. We investigated whether short-term steroid administration in UC patients refractory to maintenance therapy, with high eosinophilic infiltration in the colonic mucosa, contributed to the clinical and endoscopic improvement. Ten patients with endoscopically active and pathologically high eosinophilic infiltration, based on pathological examination using endoscopic biopsy, were examined for the clinical background when starting steroid treatment. The clinical and endoscopic improvement before and after steroid use were assessed prospectively. The average initial steroid dosage and duration of use were 21.0 mg and 102.7 days, respectively. The mean values before and after steroid use of the clinical activity index, the Mayo endoscopic subscore, and the UC endoscopic index of severity were 2.4 and 1.0, 1.8 and 0.7, and 3.9 and 1.1, respectively. All scores improved significantly after steroid use (P = .042, P = .002, P = .002, respectively). Steroids were discontinued in all patients; no patients required steroid re-administration. There may be cases of UC with eosinophilic infiltration into the colonic mucosa and resistance to maintenance treatment, suggesting that short-term steroid administration may contribute to clinical and endoscopic improvements.
- 7 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (40) , e31017
Open AccessImportance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study
Eosinophilic infiltration is sometimes observed histologically in ulcerative colitis (UC), but the effect of the degree of infiltration on the treatment course for UC is not completely understood. We investigated whether short-term steroid administration in UC patients refractory to maintenance therapy, with high eosinophilic infiltration in the colonic mucosa, contributed to the clinical and endoscopic improvement. Ten patients with endoscopically active and pathologically high eosinophilic infiltration, based on pathological examination using endoscopic biopsy, were examined for the clinical background when starting steroid treatment. The clinical and endoscopic improvement before and after steroid use were assessed prospectively. The average initial steroid dosage and duration of use were 21.0 mg and 102.7 days, respectively. The mean values before and after steroid use of the clinical activity index, the Mayo endoscopic subscore, and the UC endoscopic index of severity were 2.4 and 1.0, 1.8 and 0.7, and 3.9 and 1.1, respectively. All scores improved significantly after steroid use (P = .042, P = .002, P = .002, respectively). Steroids were discontinued in all patients; no patients required steroid re-administration. There may be cases of UC with eosinophilic infiltration into the colonic mucosa and resistance to maintenance treatment, suggesting that short-term steroid administration may contribute to clinical and endoscopic improvements.
- Open Access
- 26 May 2022
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (7) , e00501
Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
INTRODUCTION: The fecal immunochemical occult blood test (FIT) and prostaglandin E-major urinary metabolite (PGE-MUM) have been reported to predict the relapse of ulcerative colitis (UC) during remission. In this study, we directly compared FIT and PGE-MUM in predicting relapse and examined the effect of disease duration on these biomarkers. METHODS: Measurements of 2 biomarkers and endoscopic examination were performed in 73 patients with UC in remission. The patients were followed up for 12 months, and clinical relapse was evaluated. In addition, we divided the patients into long-term disease duration and short-term disease duration groups for analysis. RESULTS: Twenty-one patients (28.8%) relapsed within 12 months. FIT and PGE-MUM levels were significantly higher in the relapsed group than in the remission group. Cutoff values of FIT and PGE-MUM for predicting relapse using receiver operating characteristic analysis were 65.0 ng/mL (area under the curve [AUC]: 0.723) and 25.2 μg/g·Cr (AUC: 0.701), respectively. Patients with FIT ≥ 65.0 ng/mL and PGE-MUM ≥ 25.2 μg/g·Cr had a higher risk of clinical relapse. In the short-term disease duration group, the AUCs of FIT were larger than those of PGE-MUM using receiver operating characteristic analysis, in most instances. By contrast, the AUCs of PGE-MUM were larger than those of FIT in most cases in the long-term disease groups. DISCUSSION: FIT and PEG-MUM were highly accurate in predicting clinical relapse in UC patients with short and long disease durations in remission, respectively.
- 26 May 2022
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (7) , e00501
Open AccessPredicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
INTRODUCTION: The fecal immunochemical occult blood test (FIT) and prostaglandin E-major urinary metabolite (PGE-MUM) have been reported to predict the relapse of ulcerative colitis (UC) during remission. In this study, we directly compared FIT and PGE-MUM in predicting relapse and examined the effect of disease duration on these biomarkers. METHODS: Measurements of 2 biomarkers and endoscopic examination were performed in 73 patients with UC in remission. The patients were followed up for 12 months, and clinical relapse was evaluated. In addition, we divided the patients into long-term disease duration and short-term disease duration groups for analysis. RESULTS: Twenty-one patients (28.8%) relapsed within 12 months. FIT and PGE-MUM levels were significantly higher in the relapsed group than in the remission group. Cutoff values of FIT and PGE-MUM for predicting relapse using receiver operating characteristic analysis were 65.0 ng/mL (area under the curve [AUC]: 0.723) and 25.2 μg/g·Cr (AUC: 0.701), respectively. Patients with FIT ≥ 65.0 ng/mL and PGE-MUM ≥ 25.2 μg/g·Cr had a higher risk of clinical relapse. In the short-term disease duration group, the AUCs of FIT were larger than those of PGE-MUM using receiver operating characteristic analysis, in most instances. By contrast, the AUCs of PGE-MUM were larger than those of FIT in most cases in the long-term disease groups. DISCUSSION: FIT and PEG-MUM were highly accurate in predicting clinical relapse in UC patients with short and long disease durations in remission, respectively.